CA1118346A - Process for production of protein bound gel useful in radioimmunoassay columns - Google Patents
Process for production of protein bound gel useful in radioimmunoassay columnsInfo
- Publication number
- CA1118346A CA1118346A CA000323523A CA323523A CA1118346A CA 1118346 A CA1118346 A CA 1118346A CA 000323523 A CA000323523 A CA 000323523A CA 323523 A CA323523 A CA 323523A CA 1118346 A CA1118346 A CA 1118346A
- Authority
- CA
- Canada
- Prior art keywords
- gel
- columns
- solid
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Abstract
ABSTRACT
A solid-phase radioimmunoassay support, useful in chromatographic columns, is provided in tablet form which upon contact with an antigen-antibody solution swells to conform to the column configuration. The tablet is more easily handled, stored and transported than the known wet, chromatographic columns presently in use.
A solid-phase radioimmunoassay support, useful in chromatographic columns, is provided in tablet form which upon contact with an antigen-antibody solution swells to conform to the column configuration. The tablet is more easily handled, stored and transported than the known wet, chromatographic columns presently in use.
Description
~1834G 12,138 This invention relates in general to a process for the preparation of a solid-phase radioimmu~o2ssay support useful in ch.omatographic columns. In one aspect, this invention relates to a procecs for prepa~ing a sup-po.t in tablet form which upon contact with an antigen-antibod~ solution swells to conform to the colu~n confi-guration. In a further as~ect, this invention provides a support in tablet form which is easilv transDort~d, storec and use~ in automated clin-ical diagnostic methodclogies.
The introduction of radioim~,unoassay (RI,~,) in 1959 by Yalow and Berson as a diagnostic tracer technique to replace the slow bioassay methods then in use has re-volutionized many areas of clinical testing and research, owing to its specificity and extreme sens~tivity.
The RIA technique is based on the ability of an antibody and a specific antigen to form a reversible antigen-antibody complex. The assay is performed by adding a fixed quantity of radiolabeled antigen to samples which contain antiser~m and known amounts of "standard"
antigen. During incubation, radiolabeled antigen and ~nlabeled antigen compete for ~ limited number of bind-ing~sites on the antibody. After incubation, antibody-bound antigen is separated from the free antigen and the ratio of free to bound can be plotted on a dose-re,sponse curve. An unknown serum sample can then be assayed by the same procedure and the concentration of antigen deter-mined by referring to the standard dose-response curve.
.
(l)Nature, 184, 1648 (1959) 11183-~6 12~138 Frequentlv, the classical me-hods of RIA are cumbe;~some, time consuming and have error-producing ste?s beca1se of the requirements of multiple pipettings and test tubes, duplicate assa~s, prolonged incubation times and difficult, inefficient separation procedures Improvements in R~A have been directed most recently toward the use of solid-phas~ radioimmunoassay (SPRIA) and automation. For clarity in this disclosure, SPRIA refers to methods in which antiserur, for a specific antigen is immobilized on or in a ~-ater-insoluble support, an immunosorbent, or a maerix for which the purpose of immobilization is to facilitate the separation of free antigen f.om immobilized antiserum-bound antigen.
As indicated~ one area of improvements in radio-immunoassay is in the use of automated analystical devices.
Such devices are currently in demand not only for radio-immunoassay but for other micro-analytical studies, such as those employed in biochemical research, routing clinical testing, enzymatic studies ant the like.
Multistation analytical devices which utilize a centrifugal field have recently become available for I .- the rapid microanalysis of a wide variety of liquids, ¦ such as body fluids, e.g., blood serum, food products and the like. For example, one such instrument which has been tevelopet to automate radioimmunoassay is marketed by Union Carbide Corporation under the trademark 12,138 ~i~834~;
"Centria". The Centria System offers several inter~sting features for performing solution phzs~ i~runoassa,~s. The system consists of a) an automated pipettor which dis-pense~ sa~.ples and reagents, b) the key module, an incubator/separator, in which centrifugal force is used to initiate and terminate multiple radioassay incubations and separations simultaneouslv, and c) a gammacounter/
- computer which counts three tubes simul~aneously and converts ~ounts into concentration units. Furthe~ descrip-tion and use of the Centria System is disclosed in ~. S.
Patent Number 3,9;3,172 which issued April 27, 1976, to S. I. Shapiro and G. Etingsh~usen and is assigned to the same assignee as this invention. As indicated in this patent, the system utilizes adsorption columns to separate the components to be analyzed In the past,it was the ac-ceptea practice to purchase columns which already contained the appropriate adsorbent material and were ready for use without further preparation. While for the most part, such columns were satisfactory, they did not consistently meet the optimum requirements for clinical diagnostic techniques. When atsorption columns are utilized in devices which employ a centrifugal field, they must possess certain characteristics not ordinarily required for classical chromato~raphic methods which depend only on gravity flow. For instance, columns used in a centrifugal field may encounter column cracking or compaction due 1~183'~6 12,138 to loss of interstiti~l waters. Moreover, col~ns which have been prepared da~s or mor.ths prior to use may also encounter cracking, co~paction and water loss during storage and transit.
It has now been found that the disadvanta~es noted for such columns can be avoide~ by th~ use of a solid-phase radio~mmunoassay support which is provided in ~ablet form. The tablet is more easily handled, stored transported and used than the known wet, ch omatographic columns presently in use. The technician merel~- places a tablet in each column and upon contact with an antigen-antibody solution, the tablet swells to conform tO the column configuration.
Accordingly, one or more of the following ob-jects will be achieved by the practice of this invention.
It is an object of this invention tO provide radioimmuno-assay supports which are useful in radioimmunoassay sys-tems. Another object of this invention is to provide supports ~hich are used in columns which are utilized in an analytical system which employs centrifugal force for mixing and transferring reactants. A further object of ¦ this invention is to provide supports in the form of ¦ tablet which can be safely stored until ready for use.
Another object is to provide supports which swell within the columns to provide uniform gel substrates. A still further object is to provide a process or the preparatior of the tablets of this invention. Another object is to ~8~
provide a process of utilizing the tablets of this in-vention in radioi~munoassay. A still further object of this invention is to provide a solid-phase radioimmunoassy support comprised of a protein-bound gel of at least one antisera and chromatographic gel. ~nother object is to provide, in tablet form, a protein-bound gel of Sepharose 4B and rabbit antibody antiserum, Sepharose 4B is a trademark of Pharmacia Fine Chemicals of Piscataway, Ne~
Jersey. These and other objects will readily become apparent to those skilled in the art in the light of the teachings herein set forth.
In its broad aspect this invention is directed to a process for the preparation of a solid-phase radio-immunoassay support and its use thereof. The process com-prises the steps of:
(a~ contacting in the liquid phase to provide a protein-bound gel of (i) at least one antisera and(ii) a chromatographic gel capable of selectively restraining one or more components contained in an antigen-antibody-containing solution;
(b) freeze-drying the protein-bound gel;
(c) subdividing the dried gel to a powder, and . ~
11~83'~6 12,138 (d) forming the powder into a solid-phase support, such as a tablet.
Tablets prepared in accortance with the process of this invention have been found to be ideal~ suited for use in the chromatographic columns of the Centria System.
~ As indicated in the examples, tablets can be prepared of a predetermined size and fluid capacity sufficient for the partic-ular analysis being conducted. For exæT.ple, tablets of 80 milligrams in weight and containing approxi-mately 35 milligrams of the dried protein-bound gel were suitable for thyroid-stimulating hormone (TSH) radio-immunoassay test. The TSH test utilizes an immunological reaction in which labeled and unlabeled TSH molecules compete for binding sites on a specific antibody molecule.
The Centria System utilizes centrifugal force to mix the different reagents at the same time on a spcial disc and after incubation to separate the bound and free antigen through the columns containing a second antiboty on the solid-phase supports of this invention. The retaining means in the bottom of the column is of such a porosity and composition that all of the fluid transferred remains .. ., . in the column for absorption by the tablet. Only upon increasing the centrifugal force above that required to transfer the fluids from the disc will liquid pass out of the column.
~ 3~ 12138 The process of the present invention is particularly useful for the preparation ofi chromatographic supports which are employed in second antibody solid-phase technology.
It has been observed that many of the currently used gels, such as those market by Pharmacia Fine Chemicals of Piscataway, New Jersey under the trademark Sephadex G-25 and Sephadex A-50 encounter increasing difficulties when large molecular weight molecules are encountered. In contrast, it is believed that an advantage of the second-antibody solid^phase technology utilizing the supports of this invention is that there is no limit to the size of the antigen to which this technology may be applied. This is particularly true for supports prepared from Sepharose 4B, the trademark for a product marketed by Pharmacia Fine Chemicals of Piscataway, New Jersey.
The supports of this invention are not limited to the TSH RIA test but can be used with other antisera for a variety of analyses.
As previously indicated and as set forth in the examples, after gel preparation, the gel is bound to the appropriate antiserum and washed ln accordance with accepted techniques. Thereafter the protein-bound gel is lyophilized by freeze-drying, subdivided and compressed into tablets.
It should be noted that while the tablets of this invention are particularly suited for use in systems which utilize a centrifugal field like the aforementioned ~ 3~6 12138 Centria System, it, of course, is not limited to use in such devices. The advantages of easy storage, shipping and use also renders them idealy suited for chromatographic analyses which utilize gravity flow.
By the term "chromatographic gel" as employed throughout the specification and appended claims is meant the matrix or support which is capa~le of undergoing a multifold expansion by adsorption of fluid and selectively retaining one or more components contained in an antigen-antibody-containing solution while permitting other components to be washed free of the support.
As previously indicated, the preferred supports prepared by the process of this invention are those comprised of Sepharose 4B, a commercially available cross-linded trademarked dextran product marketed by Pharmacia.
Depending upon the desired swelling and retention character-istics, a variety of other carrier-type materials, such as Sephadex G-25 and A-50, the trademarked products of Pharmacia and agarose, marketed by Biorad Laboratories of Richmond, California, and the like, can also be processed in the solid-phase supports of this invention, L
~118346 12,138 The following examples are illustrative:
_ample 1 eparation of Solid-Phase Supports This exa~ple sets forth the procedure for the preparation of a second antibody solid-phase support.
Standard laboratory equipment and glassware (rinsed with 5N NaOH) were employed throughout. In each case, phar-maceutical grade reagents were employed.
(a) Buffer Solutions--For one litre of gel, the following buffers were employed in the support pre-paration. Their compositions are as follows:
Buffer ComPOsitiOns Quantity Prepared A NaHCO3 0.1~ ph 8 4 litres 33.6 g NaHC03/4 litres B NaHC~3 0.lM, NaCl 0.5M, ph 8 5 litres 42 g NaHC03/5 litres 146.25 g NaCl/5 litres C NaHC03 0.lM, C2H7N0 lM, ph 9 3.5 litres 29.4 g NaHCO3 `~ 20 217 ml C H7N0 16.2M )/3.5 litres ~V231 ml H~ 32%
D CH3COONa 0.1M, NaCl lM, ph 4 5 litres 41 g CH COONa ) 292.3 g3NaCl )/5 litres rv72 cc CH3COON ) . -' E Sodium borate 0.IM, NaCl lM, ph 8 6 litres . 37.2 g H B0 350.7 g ~aC~ )/6 litres ~21 cc NaOH 10N ~12g/30cc) ) F Sodium phosphate 0.03M, NaN3 4 litres 0.02%, ph 7.5 3.18 g NaH2PO4 13.76 g Na2HP04 )/ 4 litres 0.8 g NaN3 ~18346 12,138 Buffer Compositions Quantity Prepared G Same buffer + 0.2-,~ BSA, 57/, lactose, l~/c dextran T10 400 ml 400 ml Buffer F
+ 0.8 g BSA )400 ml + 20 g lactose + 4 g dextran TlO ) The carbonate buffers were prepared the morning of the dav used whereas the other buffers were prepared the 10 previous day.
(b) Gel Preparation--Cyanogen bromide (BrC~)I
10 gra~s, is dissolved i~ 1 litre of distilled ~ater in a 5 litre-beaker and thereafter is added one litre of a suspension of Sepharose(l) 4B gel. The gel container is rinsed with 1 litre of distilled water which is then added to the mixture. Thereaf~er the pH is immediately adjusted to between 10.5 and 11.5 and maintained in this range for about 5 minutes by the dropwise addition of 5~ NaOH (approximately 10 ml). The mixture containing the gel is immediately poured into a 3-litre Buchner funnel (3 porosity) and the solution withdrawn under vacuum. The gel is then washed in 5 litres of distilled water at ~4C ant thereafter 2.5 litres of Buffer A.
(c) BindinR Protein to Gel--The "cake" of gel , is recovered with a spatula and placed in the bottom of a 5-litre beaker. The Buchner is rinsed with Bùffer B
and the antirabbit antibodies antiserum is added (the volume depends on the quality of the antiserum, e.g., Wellcome serum, 50 ml). The total volume of antiserum plus Buffer B is 500 ml. This provides 1 volume of gel +
(l)Trademark of Pharmacia Gel 12 ~ 138 111~33~6 1/2 volume protein for binding. The binding is done by rotary agieation of a whisk at laboratory temperature over 4 hours.
When the binding is finished, the mixture is filtered in a Buchner. A fraction of ehe filtrate is kept at +4C for control. The gel is then washed with . 1500 ml aliquots of each of the Buffers A, B and C. For each washing the mixture is agitated for 15 minutes and the liquid withdrawn before proceeding with the next washing. After the last washing the "cake" of gel is transferred to the bottom of a S-litre beaker and the Buchner washed with 2 litres of Buffer C which are trans-ferred to the beaker to provide 1 volume to gel and 1/2 volume of Buffer C. After agitation by rotation for 1 hour, the mixture is left to stand overnight. After stanting overnight, the mixture is agitated for lS minutes and the suspension poured into the Buchner and the liquid withdrawn. The ge,l is then rinsed and washed in accordance with the following sequence:
The gel is agitated 15 minutes with 1500 ml of Buffer A, and the liquit withdrawn.
Washing 1500 cc Buffer B, agitation 15 minutes --' withdrawal of liquid 1500 cc Buffer D
agitation 15 minutes withdrawal of liquid 1500 cc Buffer E
agitation 15 minutes withdrawal o~ liquid~
~ ~18346 12,138 This washing cycle with Buffe s D and E is performed 3 times.
1500 cc of Buffer E
agitation 15 minutes withdrawal of liquid 1500 cc of Buffer F
agitation 15 minutes withdrawal of liquid.
The gel is then reco~stituted in a l-litre beaker with 400 cc of Buffer G.
(d) LyoPhilisation--The gel is transferred into two stainless steel trays, and then freeze-dried.
Thereafter, the gel is tested to determine the weight necessary to recover 400,~1 of incubation soluti~n. This weight is then checked to ensure that it corresponds to the maximum binding capacity;
(e) Tablet Preparation-~After lyophilisation of the gel has been completed, the solid is pulverized ; if necessary to provide a homogeneous product. The pro-duct is then sieved on a sieve having a porosity of 0.25 mm (Saulas et Cie., 16, Rue du Buisson St. Louis, :: :
75010 ~aris). Tablets such as 80 mg tablets are formu-lated blending approximately 35 m~ of the sieved product, approximately 44 mg of dicalcium phosphate and 1 mg - magnesium stearate, and pressing on a tabletting machine, (Frogerais type AM, 15~ Rue de l'Yseu, 9~440 Vitry/Seine) at 4000 kg/cm2.
ExamPle 2 Clinical human blood serum samples were analyzed to determine the level of th~roid-stimulating hormone ~i~8346 1~, 138 (TSH) therein using the Centria System marketed by Union Carbide Corporation Samples of unkno~n TSH lev~'s and standards solutions of known levels were processed simultaneousl~m This ~as accomplished by loading 20 cup positions with 250 microlitres each of a particular clinical serum sample and 16 cup positions with 250 microlitres of standard solutions. The standard TSH
solutions employed contained O.O~U/ml, 2.0~U/r.,l, 4.0M~/ml, lO~U/ml, 20U~/ml, 4~' /ml and lOOY~/~.l, respectively.
The 125 I TSH was reconstituted with 5 ml of distilled water to give about 20,000 cpm per 50~1. The TSH anti-serum was reconstituted with 17 ml of distilled water and the ~SB buffer reconstituted with 3 ml of distilled water.
The reagents and samples ~50~1) were pipetted automatically into the appropriate cavities of the transfer discs. The transfer disc is thereafter placed on the incubation separator module. After mix-ing of the reagents and samplcs, the mixture was allowed to incubate for 24 or 48 hour~. After this incubation, the column ring was then lo~ded with test tubes and l , columns equipped with hydrophobic plugs in the incubator ¦ separator module. Into each column was placed a tablet prepared in accordance with the previous example.
The mixture is transferred on the columns by using the centrifugal force. The tablet swells and the solid phase binds the whole antibody specific to the TSH. The solid ~83~6 12,138 phase is washed after 10 minutes of second incubation by approximately 2.5ml of a buffer solution (phosphate buffer 0.015 ~ ph 7.5). The columns are thereafter measured on the third module of the centria and the mea-surements recorded from the computer.
Although the invention has been illustrated by the foregoing examples, it is not to be construed as being limited to the materials employed therein, but rather, the invention encompasses the generic area as hereinbefore disclosed. Various modifications and em-bodiments of this invention can be made without depart-ing from the spirit and scope thereof.
The introduction of radioim~,unoassay (RI,~,) in 1959 by Yalow and Berson as a diagnostic tracer technique to replace the slow bioassay methods then in use has re-volutionized many areas of clinical testing and research, owing to its specificity and extreme sens~tivity.
The RIA technique is based on the ability of an antibody and a specific antigen to form a reversible antigen-antibody complex. The assay is performed by adding a fixed quantity of radiolabeled antigen to samples which contain antiser~m and known amounts of "standard"
antigen. During incubation, radiolabeled antigen and ~nlabeled antigen compete for ~ limited number of bind-ing~sites on the antibody. After incubation, antibody-bound antigen is separated from the free antigen and the ratio of free to bound can be plotted on a dose-re,sponse curve. An unknown serum sample can then be assayed by the same procedure and the concentration of antigen deter-mined by referring to the standard dose-response curve.
.
(l)Nature, 184, 1648 (1959) 11183-~6 12~138 Frequentlv, the classical me-hods of RIA are cumbe;~some, time consuming and have error-producing ste?s beca1se of the requirements of multiple pipettings and test tubes, duplicate assa~s, prolonged incubation times and difficult, inefficient separation procedures Improvements in R~A have been directed most recently toward the use of solid-phas~ radioimmunoassay (SPRIA) and automation. For clarity in this disclosure, SPRIA refers to methods in which antiserur, for a specific antigen is immobilized on or in a ~-ater-insoluble support, an immunosorbent, or a maerix for which the purpose of immobilization is to facilitate the separation of free antigen f.om immobilized antiserum-bound antigen.
As indicated~ one area of improvements in radio-immunoassay is in the use of automated analystical devices.
Such devices are currently in demand not only for radio-immunoassay but for other micro-analytical studies, such as those employed in biochemical research, routing clinical testing, enzymatic studies ant the like.
Multistation analytical devices which utilize a centrifugal field have recently become available for I .- the rapid microanalysis of a wide variety of liquids, ¦ such as body fluids, e.g., blood serum, food products and the like. For example, one such instrument which has been tevelopet to automate radioimmunoassay is marketed by Union Carbide Corporation under the trademark 12,138 ~i~834~;
"Centria". The Centria System offers several inter~sting features for performing solution phzs~ i~runoassa,~s. The system consists of a) an automated pipettor which dis-pense~ sa~.ples and reagents, b) the key module, an incubator/separator, in which centrifugal force is used to initiate and terminate multiple radioassay incubations and separations simultaneouslv, and c) a gammacounter/
- computer which counts three tubes simul~aneously and converts ~ounts into concentration units. Furthe~ descrip-tion and use of the Centria System is disclosed in ~. S.
Patent Number 3,9;3,172 which issued April 27, 1976, to S. I. Shapiro and G. Etingsh~usen and is assigned to the same assignee as this invention. As indicated in this patent, the system utilizes adsorption columns to separate the components to be analyzed In the past,it was the ac-ceptea practice to purchase columns which already contained the appropriate adsorbent material and were ready for use without further preparation. While for the most part, such columns were satisfactory, they did not consistently meet the optimum requirements for clinical diagnostic techniques. When atsorption columns are utilized in devices which employ a centrifugal field, they must possess certain characteristics not ordinarily required for classical chromato~raphic methods which depend only on gravity flow. For instance, columns used in a centrifugal field may encounter column cracking or compaction due 1~183'~6 12,138 to loss of interstiti~l waters. Moreover, col~ns which have been prepared da~s or mor.ths prior to use may also encounter cracking, co~paction and water loss during storage and transit.
It has now been found that the disadvanta~es noted for such columns can be avoide~ by th~ use of a solid-phase radio~mmunoassay support which is provided in ~ablet form. The tablet is more easily handled, stored transported and used than the known wet, ch omatographic columns presently in use. The technician merel~- places a tablet in each column and upon contact with an antigen-antibody solution, the tablet swells to conform tO the column configuration.
Accordingly, one or more of the following ob-jects will be achieved by the practice of this invention.
It is an object of this invention tO provide radioimmuno-assay supports which are useful in radioimmunoassay sys-tems. Another object of this invention is to provide supports ~hich are used in columns which are utilized in an analytical system which employs centrifugal force for mixing and transferring reactants. A further object of ¦ this invention is to provide supports in the form of ¦ tablet which can be safely stored until ready for use.
Another object is to provide supports which swell within the columns to provide uniform gel substrates. A still further object is to provide a process or the preparatior of the tablets of this invention. Another object is to ~8~
provide a process of utilizing the tablets of this in-vention in radioi~munoassay. A still further object of this invention is to provide a solid-phase radioimmunoassy support comprised of a protein-bound gel of at least one antisera and chromatographic gel. ~nother object is to provide, in tablet form, a protein-bound gel of Sepharose 4B and rabbit antibody antiserum, Sepharose 4B is a trademark of Pharmacia Fine Chemicals of Piscataway, Ne~
Jersey. These and other objects will readily become apparent to those skilled in the art in the light of the teachings herein set forth.
In its broad aspect this invention is directed to a process for the preparation of a solid-phase radio-immunoassay support and its use thereof. The process com-prises the steps of:
(a~ contacting in the liquid phase to provide a protein-bound gel of (i) at least one antisera and(ii) a chromatographic gel capable of selectively restraining one or more components contained in an antigen-antibody-containing solution;
(b) freeze-drying the protein-bound gel;
(c) subdividing the dried gel to a powder, and . ~
11~83'~6 12,138 (d) forming the powder into a solid-phase support, such as a tablet.
Tablets prepared in accortance with the process of this invention have been found to be ideal~ suited for use in the chromatographic columns of the Centria System.
~ As indicated in the examples, tablets can be prepared of a predetermined size and fluid capacity sufficient for the partic-ular analysis being conducted. For exæT.ple, tablets of 80 milligrams in weight and containing approxi-mately 35 milligrams of the dried protein-bound gel were suitable for thyroid-stimulating hormone (TSH) radio-immunoassay test. The TSH test utilizes an immunological reaction in which labeled and unlabeled TSH molecules compete for binding sites on a specific antibody molecule.
The Centria System utilizes centrifugal force to mix the different reagents at the same time on a spcial disc and after incubation to separate the bound and free antigen through the columns containing a second antiboty on the solid-phase supports of this invention. The retaining means in the bottom of the column is of such a porosity and composition that all of the fluid transferred remains .. ., . in the column for absorption by the tablet. Only upon increasing the centrifugal force above that required to transfer the fluids from the disc will liquid pass out of the column.
~ 3~ 12138 The process of the present invention is particularly useful for the preparation ofi chromatographic supports which are employed in second antibody solid-phase technology.
It has been observed that many of the currently used gels, such as those market by Pharmacia Fine Chemicals of Piscataway, New Jersey under the trademark Sephadex G-25 and Sephadex A-50 encounter increasing difficulties when large molecular weight molecules are encountered. In contrast, it is believed that an advantage of the second-antibody solid^phase technology utilizing the supports of this invention is that there is no limit to the size of the antigen to which this technology may be applied. This is particularly true for supports prepared from Sepharose 4B, the trademark for a product marketed by Pharmacia Fine Chemicals of Piscataway, New Jersey.
The supports of this invention are not limited to the TSH RIA test but can be used with other antisera for a variety of analyses.
As previously indicated and as set forth in the examples, after gel preparation, the gel is bound to the appropriate antiserum and washed ln accordance with accepted techniques. Thereafter the protein-bound gel is lyophilized by freeze-drying, subdivided and compressed into tablets.
It should be noted that while the tablets of this invention are particularly suited for use in systems which utilize a centrifugal field like the aforementioned ~ 3~6 12138 Centria System, it, of course, is not limited to use in such devices. The advantages of easy storage, shipping and use also renders them idealy suited for chromatographic analyses which utilize gravity flow.
By the term "chromatographic gel" as employed throughout the specification and appended claims is meant the matrix or support which is capa~le of undergoing a multifold expansion by adsorption of fluid and selectively retaining one or more components contained in an antigen-antibody-containing solution while permitting other components to be washed free of the support.
As previously indicated, the preferred supports prepared by the process of this invention are those comprised of Sepharose 4B, a commercially available cross-linded trademarked dextran product marketed by Pharmacia.
Depending upon the desired swelling and retention character-istics, a variety of other carrier-type materials, such as Sephadex G-25 and A-50, the trademarked products of Pharmacia and agarose, marketed by Biorad Laboratories of Richmond, California, and the like, can also be processed in the solid-phase supports of this invention, L
~118346 12,138 The following examples are illustrative:
_ample 1 eparation of Solid-Phase Supports This exa~ple sets forth the procedure for the preparation of a second antibody solid-phase support.
Standard laboratory equipment and glassware (rinsed with 5N NaOH) were employed throughout. In each case, phar-maceutical grade reagents were employed.
(a) Buffer Solutions--For one litre of gel, the following buffers were employed in the support pre-paration. Their compositions are as follows:
Buffer ComPOsitiOns Quantity Prepared A NaHCO3 0.1~ ph 8 4 litres 33.6 g NaHC03/4 litres B NaHC~3 0.lM, NaCl 0.5M, ph 8 5 litres 42 g NaHC03/5 litres 146.25 g NaCl/5 litres C NaHC03 0.lM, C2H7N0 lM, ph 9 3.5 litres 29.4 g NaHCO3 `~ 20 217 ml C H7N0 16.2M )/3.5 litres ~V231 ml H~ 32%
D CH3COONa 0.1M, NaCl lM, ph 4 5 litres 41 g CH COONa ) 292.3 g3NaCl )/5 litres rv72 cc CH3COON ) . -' E Sodium borate 0.IM, NaCl lM, ph 8 6 litres . 37.2 g H B0 350.7 g ~aC~ )/6 litres ~21 cc NaOH 10N ~12g/30cc) ) F Sodium phosphate 0.03M, NaN3 4 litres 0.02%, ph 7.5 3.18 g NaH2PO4 13.76 g Na2HP04 )/ 4 litres 0.8 g NaN3 ~18346 12,138 Buffer Compositions Quantity Prepared G Same buffer + 0.2-,~ BSA, 57/, lactose, l~/c dextran T10 400 ml 400 ml Buffer F
+ 0.8 g BSA )400 ml + 20 g lactose + 4 g dextran TlO ) The carbonate buffers were prepared the morning of the dav used whereas the other buffers were prepared the 10 previous day.
(b) Gel Preparation--Cyanogen bromide (BrC~)I
10 gra~s, is dissolved i~ 1 litre of distilled ~ater in a 5 litre-beaker and thereafter is added one litre of a suspension of Sepharose(l) 4B gel. The gel container is rinsed with 1 litre of distilled water which is then added to the mixture. Thereaf~er the pH is immediately adjusted to between 10.5 and 11.5 and maintained in this range for about 5 minutes by the dropwise addition of 5~ NaOH (approximately 10 ml). The mixture containing the gel is immediately poured into a 3-litre Buchner funnel (3 porosity) and the solution withdrawn under vacuum. The gel is then washed in 5 litres of distilled water at ~4C ant thereafter 2.5 litres of Buffer A.
(c) BindinR Protein to Gel--The "cake" of gel , is recovered with a spatula and placed in the bottom of a 5-litre beaker. The Buchner is rinsed with Bùffer B
and the antirabbit antibodies antiserum is added (the volume depends on the quality of the antiserum, e.g., Wellcome serum, 50 ml). The total volume of antiserum plus Buffer B is 500 ml. This provides 1 volume of gel +
(l)Trademark of Pharmacia Gel 12 ~ 138 111~33~6 1/2 volume protein for binding. The binding is done by rotary agieation of a whisk at laboratory temperature over 4 hours.
When the binding is finished, the mixture is filtered in a Buchner. A fraction of ehe filtrate is kept at +4C for control. The gel is then washed with . 1500 ml aliquots of each of the Buffers A, B and C. For each washing the mixture is agitated for 15 minutes and the liquid withdrawn before proceeding with the next washing. After the last washing the "cake" of gel is transferred to the bottom of a S-litre beaker and the Buchner washed with 2 litres of Buffer C which are trans-ferred to the beaker to provide 1 volume to gel and 1/2 volume of Buffer C. After agitation by rotation for 1 hour, the mixture is left to stand overnight. After stanting overnight, the mixture is agitated for lS minutes and the suspension poured into the Buchner and the liquid withdrawn. The ge,l is then rinsed and washed in accordance with the following sequence:
The gel is agitated 15 minutes with 1500 ml of Buffer A, and the liquit withdrawn.
Washing 1500 cc Buffer B, agitation 15 minutes --' withdrawal of liquid 1500 cc Buffer D
agitation 15 minutes withdrawal of liquid 1500 cc Buffer E
agitation 15 minutes withdrawal o~ liquid~
~ ~18346 12,138 This washing cycle with Buffe s D and E is performed 3 times.
1500 cc of Buffer E
agitation 15 minutes withdrawal of liquid 1500 cc of Buffer F
agitation 15 minutes withdrawal of liquid.
The gel is then reco~stituted in a l-litre beaker with 400 cc of Buffer G.
(d) LyoPhilisation--The gel is transferred into two stainless steel trays, and then freeze-dried.
Thereafter, the gel is tested to determine the weight necessary to recover 400,~1 of incubation soluti~n. This weight is then checked to ensure that it corresponds to the maximum binding capacity;
(e) Tablet Preparation-~After lyophilisation of the gel has been completed, the solid is pulverized ; if necessary to provide a homogeneous product. The pro-duct is then sieved on a sieve having a porosity of 0.25 mm (Saulas et Cie., 16, Rue du Buisson St. Louis, :: :
75010 ~aris). Tablets such as 80 mg tablets are formu-lated blending approximately 35 m~ of the sieved product, approximately 44 mg of dicalcium phosphate and 1 mg - magnesium stearate, and pressing on a tabletting machine, (Frogerais type AM, 15~ Rue de l'Yseu, 9~440 Vitry/Seine) at 4000 kg/cm2.
ExamPle 2 Clinical human blood serum samples were analyzed to determine the level of th~roid-stimulating hormone ~i~8346 1~, 138 (TSH) therein using the Centria System marketed by Union Carbide Corporation Samples of unkno~n TSH lev~'s and standards solutions of known levels were processed simultaneousl~m This ~as accomplished by loading 20 cup positions with 250 microlitres each of a particular clinical serum sample and 16 cup positions with 250 microlitres of standard solutions. The standard TSH
solutions employed contained O.O~U/ml, 2.0~U/r.,l, 4.0M~/ml, lO~U/ml, 20U~/ml, 4~' /ml and lOOY~/~.l, respectively.
The 125 I TSH was reconstituted with 5 ml of distilled water to give about 20,000 cpm per 50~1. The TSH anti-serum was reconstituted with 17 ml of distilled water and the ~SB buffer reconstituted with 3 ml of distilled water.
The reagents and samples ~50~1) were pipetted automatically into the appropriate cavities of the transfer discs. The transfer disc is thereafter placed on the incubation separator module. After mix-ing of the reagents and samplcs, the mixture was allowed to incubate for 24 or 48 hour~. After this incubation, the column ring was then lo~ded with test tubes and l , columns equipped with hydrophobic plugs in the incubator ¦ separator module. Into each column was placed a tablet prepared in accordance with the previous example.
The mixture is transferred on the columns by using the centrifugal force. The tablet swells and the solid phase binds the whole antibody specific to the TSH. The solid ~83~6 12,138 phase is washed after 10 minutes of second incubation by approximately 2.5ml of a buffer solution (phosphate buffer 0.015 ~ ph 7.5). The columns are thereafter measured on the third module of the centria and the mea-surements recorded from the computer.
Although the invention has been illustrated by the foregoing examples, it is not to be construed as being limited to the materials employed therein, but rather, the invention encompasses the generic area as hereinbefore disclosed. Various modifications and em-bodiments of this invention can be made without depart-ing from the spirit and scope thereof.
Claims (7)
1. A process for the preparation of a solid-phase support useful in radioimmunoassay columns which support swells upon contact with an antigen-antibody-containing solution to conform to the shape of said collumns, which process comprises the steps of:
(a) contacting in the liquid phase to provide a protein-bound gel of (i) at least one antisera and (ii) a chromatographic gel, said protein-bound gel being capable of selectively retaining one or more components contained in an antigen-antibody-containing solution.
(b) freeze-drying said protein-bound gel, (c) subdividing said dried gel to a powder, and (d) forming said powder into a solid-phase support.
(a) contacting in the liquid phase to provide a protein-bound gel of (i) at least one antisera and (ii) a chromatographic gel, said protein-bound gel being capable of selectively retaining one or more components contained in an antigen-antibody-containing solution.
(b) freeze-drying said protein-bound gel, (c) subdividing said dried gel to a powder, and (d) forming said powder into a solid-phase support.
2. The process of claim 1 wherein said powder is of a particle size sufficiently small to pass through a sieve having a porosity of 0.25 millimeters.
3. The process of claim 1 wherein said solid-phase support is in the form of a tablet.
4. The process of claim 1 wherein said solid-phase support is in the form of a tablet, said tablet being comprised of said dried protein-bound gel, dicalcium phosphate and magnesium stearate.
5. The process of claim 1 wherein said solid-phase support is in the form of a tablet and contains sufficient protein-bound gel to adsorb at least .400 microlitres of an antigen-antibody-containing solution.
6. A solid-phase support useful in radioimmunoassay columns, which support swells upon contact with an antigen-antibody-containing solution to conform to the shape of said columns, said support comprised of at least one antisera bound to a chromatographic gel and capable of selectively retaining one or more component contained in an antigen-antibody-containing solution.
7. A radioimmunoassay procedure wherein samples and reagents are mixed and transferred to chromatographic columns by means of centrifugal force, the improvement which comprises placing in said columns tablets prepared by the process of claim 1, and increasing said centrifugal force to an amount necessary to mix said samples and reagents and transfer them to the column containing said tablets, whereby said tablets swell and conform to the configuration of said columns.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/891,650 US4170454A (en) | 1978-03-30 | 1978-03-30 | Process for the preparation of a solid-phase radioimmunoassay support and use thereof |
| US891,650 | 1978-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1118346A true CA1118346A (en) | 1982-02-16 |
Family
ID=25398594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000323523A Expired CA1118346A (en) | 1978-03-30 | 1979-03-15 | Process for production of protein bound gel useful in radioimmunoassay columns |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4170454A (en) |
| JP (1) | JPS5925185B2 (en) |
| AU (1) | AU528893B2 (en) |
| CA (1) | CA1118346A (en) |
| CH (1) | CH642459A5 (en) |
| DE (1) | DE2912239C2 (en) |
| FR (1) | FR2421381A1 (en) |
| GB (1) | GB2017909B (en) |
| SE (1) | SE437731B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244694A (en) * | 1978-03-31 | 1981-01-13 | Union Carbide Corporation | Reactor/separator device for use in automated solid phase immunoassay |
| US4259207A (en) * | 1979-09-19 | 1981-03-31 | American Hospital Supply Corporation | Suspending medium for immunologic reactions |
| US4623629A (en) | 1983-10-31 | 1986-11-18 | Daniel Kerschensteiner | Solid-phase immunoassay support and method of use thereof |
| US5229268A (en) * | 1986-07-14 | 1993-07-20 | Abbott Laboratories | Method for diagnostic immunoassay by solid phase separation |
| NO892244L (en) * | 1988-06-06 | 1989-12-07 | Photest Diagnostics Inc | PROCEDURE FOR IMMUNDIAGNOSTIC DETERMINATION. |
| US7108800B2 (en) | 2004-05-14 | 2006-09-19 | Nalco Company | Method for preventing the agglomeration or generation of dust from a particulate material comprising coal |
| JP6023943B2 (en) * | 2009-12-22 | 2016-11-09 | ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ | Method for dry-packing chromatography columns |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA990416A (en) * | 1972-04-19 | 1976-06-01 | Sieuwko J. Mantel | Device suitable for use in radioimmunoassay and method of determining the content of a specific hormone in a serum sample |
| FR1527279A (en) * | 1966-06-02 | 1968-05-31 | Pharmacia Ab | Method and reagent for determining proteins and polypeptides, eg hormones, in an aqueous sample |
| SE343949B (en) * | 1966-06-02 | 1972-03-20 | Pharmacia Ab | |
| US3996162A (en) * | 1970-02-27 | 1976-12-07 | Nuclear Medical Laboratories, Inc. | Analytical sorbent and method of use |
| AU2919171A (en) * | 1970-05-27 | 1972-11-30 | Pharmacia Ab | A method for carrying out tests, a reagent andan additive for carrying out the method |
| US3659104A (en) * | 1970-06-29 | 1972-04-25 | Univ Jerusalem The | Method of measuring serum thyroxine |
| IL42105A (en) * | 1973-04-25 | 1976-08-31 | Yissum Res Dev Co | Process for determination of triiodothyronine |
| US3925017A (en) * | 1973-05-01 | 1975-12-09 | Wisconsin Alumni Res Found | Preparation of dry, porous gel particles having high water regain for liquid sampling |
| US4070348A (en) * | 1973-07-25 | 1978-01-24 | Rohm Gmbh | Water-swellable, bead copolymer |
| US4039652A (en) * | 1973-10-11 | 1977-08-02 | Miles Laboratories, Inc. | Column method of immunoassay employing an immobilized binding partner |
| US3980764A (en) * | 1973-11-05 | 1976-09-14 | Curtis Nuclear Corporation | Polymeric competitive protein binding adsorbents for radioassey |
| US3953172A (en) * | 1974-05-10 | 1976-04-27 | Union Carbide Corporation | Method and apparatus for assaying liquid materials |
| US3947352A (en) * | 1974-05-31 | 1976-03-30 | Pedro Cuatrecasas | Polysaccharide matrices for use as adsorbents in affinity chromatography techniques |
| US4061466A (en) * | 1974-10-16 | 1977-12-06 | Ingvar Gosta Holger Sjoholm | Biologically active composition and the use thereof |
| US4018883A (en) * | 1975-03-10 | 1977-04-19 | Nichols Institute For Endocrinology | Thyroxine (T4) radioimmunoassay |
| JPS5267395A (en) * | 1975-12-01 | 1977-06-03 | Japan Exlan Co Ltd | Opening prcess for high density filling column in liquid chromatography |
-
1978
- 1978-03-30 US US05/891,650 patent/US4170454A/en not_active Expired - Lifetime
-
1979
- 1979-03-15 CA CA000323523A patent/CA1118346A/en not_active Expired
- 1979-03-28 DE DE2912239A patent/DE2912239C2/en not_active Expired
- 1979-03-29 SE SE7902810A patent/SE437731B/en unknown
- 1979-03-29 GB GB7910983A patent/GB2017909B/en not_active Expired
- 1979-03-29 JP JP54036350A patent/JPS5925185B2/en not_active Expired
- 1979-03-29 CH CH293879A patent/CH642459A5/en not_active IP Right Cessation
- 1979-03-29 FR FR7907903A patent/FR2421381A1/en active Granted
- 1979-03-29 AU AU45580/79A patent/AU528893B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE2912239C2 (en) | 1982-12-30 |
| AU528893B2 (en) | 1983-05-19 |
| FR2421381A1 (en) | 1979-10-26 |
| US4170454A (en) | 1979-10-09 |
| DE2912239A1 (en) | 1979-10-04 |
| SE7902810L (en) | 1979-10-01 |
| GB2017909A (en) | 1979-10-10 |
| CH642459A5 (en) | 1984-04-13 |
| GB2017909B (en) | 1983-01-19 |
| SE437731B (en) | 1985-03-11 |
| FR2421381B1 (en) | 1984-03-16 |
| JPS5925185B2 (en) | 1984-06-15 |
| JPS54143200A (en) | 1979-11-08 |
| AU4558079A (en) | 1979-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4244694A (en) | Reactor/separator device for use in automated solid phase immunoassay | |
| US4434236A (en) | Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue | |
| AU609241B2 (en) | Ion-capture assays and devices | |
| CA1261745A (en) | Methods of assay | |
| US4659678A (en) | Immunoassay of antigens | |
| De Alwis et al. | Rapid heterogeneous competitive electrochemical immunoassay for IgG in the picomole range | |
| EP0073593A1 (en) | Size-exclusion heterogeneous immunoassay | |
| EP0027008A1 (en) | Apparatus and method for conducting simultaneous solid phase tests for multiple mobile components in fluids | |
| WO1994027150A1 (en) | Method for assaying more than one immunological ligand, and assay reagent and kit therefor | |
| US4865997A (en) | Assay for ligands by separating bound and free tracer from sample | |
| JPH06500853A (en) | Disposable reaction container for solid-phase immunoassay and method for measuring components detectable by immunoreaction | |
| US4317810A (en) | Waffle-like matrix for immunoassay and preparation thereof | |
| US4283383A (en) | Analysis of biological fluids | |
| CA2046130A1 (en) | Biologically active reagent, analytical element and methods for use of the reagent | |
| US4410634A (en) | Method of passively adsorbing immuno-reactive haptens to solid phases | |
| CA1118346A (en) | Process for production of protein bound gel useful in radioimmunoassay columns | |
| CA1146853A (en) | Method of passively adsorbing immuno-reactive haptens to solid phases | |
| US4166844A (en) | Solid phase separation technique for use in radioimmunoassays | |
| AU618580B2 (en) | Immunoassay utilizing biotin bridge with universal solid phase | |
| US4034073A (en) | Composite for biased solid phase radioimmunoassay of triiodothyronine and thyroxine | |
| JPS6342229B2 (en) | ||
| AU595899B2 (en) | Method for diagnostic immunoassay by solid phase separation | |
| EP0336647A2 (en) | Determination of arachidonic acid derivatives and kits therefore | |
| Kakabakos et al. | Immobilization of immunoglobulins onto surface-treated and untreated polystyrene beads for radioimmunoassays | |
| CN218481404U (en) | Kit for synchronously detecting morphine and methamphetamine based on flow-type fluorescence technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |